title: Influence of pentoxifylline and interferon-alpha on prevention of stricture due to corrosive esophagitis. An experimental study in the rat.
abstract: The effects of pentoxifylline (PTX) and interferon alpha (IFN-alpha) in the prevention of strictures due to corrosive esophagitis in rats were investigated. Forty rats were randomly divided into four equal groups. Corrosive esophagitis was induced in all groups by application of 37.5% NaOH to the distal esophagus for a period of 90 s followed by saline rinse. Histopathologic damage was significantly lower in the PTX and IFN-alpha-treated groups than in the untreated group. During the study period, PTX and INF-alpha-treated animals showed a significant increase in body weight when compared to controls. However, PTX provided more significant prevention of stricture formation than IFN-alpha. In the PTX-treated group, the wall thickness and quantity of hydroxyprolin were significantly lower than in the untreated and IFN-alpha-treated groups. Stenosis index in the PTX group was significantly reduced compared to the control group. PTX prevents the stricture formation due to corrosive esophagitis in this experimental model. IFN-alpha was also shown to prevent stricture formation when considering amelioration of histopathologic damage and increase in body weight.
authors.affiliation: Department of Surgery, Cerrahpasa Medical Faculty of Istanbul University, Istanbul, Turkey.
authors.forename: B B
authors.initials: BB
authors.lastname: Apaydin
authors.forename: M
authors.initials: M
authors.lastname: Paksoy
authors.forename: T
authors.initials: T
authors.lastname: Artiş
authors.forename: D A
authors.initials: DA
authors.lastname: Sahin
authors.forename: H
authors.initials: H
authors.lastname: Aki
authors.forename: E
authors.initials: E
authors.lastname: Uslu
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D003251:Constriction, Pathologic / Q000473:pathology; D004940:Esophageal Stenosis / Q000517:prevention & control*; D004941:Esophagitis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004947:Esophagus / Q000378:metabolism / Q000473:pathology; D006909:Hydroxyproline / Q000378:metabolism; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D010431:Pentoxifylline / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index
chemical_list: D000893:Anti-Inflammatory Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D006909:Hydroxyproline; D010431:Pentoxifylline